生物技术公司Precision BioSciences Inc宣布,其合作伙伴TG Therapeutics已向其支付750万美元,作为Azer-Cel疗法在多发性硬化症临床研发中达成重要里程碑的款项。
生物技术公司Precision BioSciences Inc宣布,其合作伙伴TG Therapeutics已向其支付750万美元,作为Azer-Cel疗法在多发性硬化症临床研发中达成重要里程碑的款项。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.